Many pharmaceutical, medical device and life science companies invest considerable effort and skill in building team based Continuous Improvement/ Lean/ Six Sigma/ OPEX (apply your own label as appropriate!) programs yet still struggle with the day-to-day drain on resources from recurring deviations, long investigations, reactive CAPAs and ineffective root cause analysis.
The question is whether these initiatives and improvement toolkits really enable organisation's to 'connect the dots' across the business in order to sustain improvement. Moreover, is your program capable of objectively measuring and monitoring the effectiveness of the effort by designing measures that matter, not just the traditional Key Performance Indicators (KPIs) but also designing local Key Behavioural Indicators (KBIs) that allow the teams to relate the impact of their efforts to the outcomes that matter to the business and the patient.
Interested? Then don't miss the insights from the St. Gallen FDA Quality Metrics and Quality Culture research, a one day seminar hosted by TU Dublin (DIT) in Dublin on 6th Feb. 2019.
The event will be led by Prof. Dr. Thomas Friedli and Dr. Nuala Calnan (Dublin Institute of Technology).
Initially shared on LinkedIn